Journal
INTERNATIONAL JOURNAL OF NEUROSCIENCE
Volume 132, Issue 4, Pages 352-361Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/00207454.2020.1815733
Keywords
inflammatory neuropathy; intravenous immunoglobulin; therapeutic dosing; outcome measure
Categories
Funding
- Medical Research Council (MRC), MRC Centre grant [G0601943]
- National Institutes of Neurological Diseases and Stroke
- office of Rare Diseases [U54NS065712]
- National Institute of Health Research, University College London Hospitals, Biomedical Research Centre
- MRC [G0601943] Funding Source: UKRI
Ask authors/readers for more resources
High-dose IVIg has been proven to be safe and effective in restoring strength and ability to participate in daily activities for patients with CIDP and MMNCB. Individualized assessment plays a crucial role in improving treatment outcomes.
Background Intravenous immunoglobulin (IVIg) has short and long-term efficacy in both chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy with conduction block (MMNCB). There is potential for under and over-treatment if trial regimens are strictly adhered to in clinical practice where titrating dose to clinical response is recommended. Methods We report the response to high-dose IVIg (>2 g/kg/6 weeks) in a subgroup of patients with definite CIDP or MMNCB who were unresponsive to 'usual' dosing. IVIg frequency and dosing was determined for each individual by subjective and objective outcome measures for impairment, grip strength, and activity and participation. Results Six patients (three with chronic inflammatory demyelinating polyneuropathy (CIDP), three with MMN) were included. Two patients (one CIDP and one MMNCB) returned to full-time work on fractionated IVIg doses of 5 g/kg/month and 9 g/kg/month. Patient three (CIDP) failed numerous other immunosuppressants but responded to short-term fractionated 4 g/kg/month of IVIg. Patient four has severe, refractory, childhood-onset CIDP, remains stable but dependent currently on 6.9 g/kg/month of IVIg. Patients five and six, both with MMNCB, required short term 4.5-5 g/kg/month to recover significant bilateral hand strength. No IVIg-related adverse events occurred in any individual. Conclusions These six cases demonstrate the safety and effectiveness of a treatment approach that includes individualised but evidence-based clinical assessment and, when necessary, high-doses of IVIg to restore patients' strength and ability to participate in activities of daily activities. Careful patient selection is important.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available